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Abstract
The interaction between stromal cell-derived factor-1 (SDF-1) with CXCR4 chemokine receptors plays an important role in
hematopoiesis following hematopoietic stem cell transplantation. We examined the efficacy of post transplant
administration of a specific CXCR4 antagonist (AMD3100) in improving animal survival and in enhancing donor
hematopoietic cell engraftment using a congeneic mouse transplantation model. AMD3100 was administered
subcutaneously at 5 mg/kg body weight 3 times a week beginning at day +2 post-transplant. Post-transplant
administration of AMD3100 significantly improves animal survival. AMD3100 reduces pro-inflammatory cytokine/chemokine
production. Furthermore, post transplant administration of AMD3100 selectively enhances donor cell engraftment and
promotes recovery of all donor cell lineages (myeloid cells, T and B lymphocytes, erythrocytes and platelets). This
enhancement results from a combined effect of increased marrow niche availability and greater cell division induced by
AMD3100. Our studies shed new lights into the biological roles of SDF-1/CXCR4 interaction in hematopoietic stem cell
engraftment following transplantation and in transplant-related mortality. Our results indicate that AMD3100 provides a
novel approach for enhancing hematological recovery following transplantation, and will likely benefit patients undergoing
transplantation.
Citation: Kang Y, Chen BJ, DeOliveira D, Mito J, Chao NJ (2010) Selective Enhancement of Donor Hematopoietic Cell Engraftment by the CXCR4 Antagonist
AMD3100 in a Mouse Transplantation Model. PLoS ONE 5(6): e11316. doi:10.1371/journal.pone.0011316
Editor: Annarosa Leri, Harvard Medical School, United States of America
Received November 20, 2009; Accepted May 27, 2010; Published June 28, 2010
Copyright:  2010 Kang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by National Institutes of Health (NIH) grant 1U19 AI067798-01 (PI: NJC) and a research grant from Genzyme Corp (PI: NJC).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The study was supported in part by a research grant from Genzyme Corp. There are no competing interests relating to employment,
consultancy, or patents. The research support does not alter the authors’ adherence to all the PLoS ONE policies.
* E-mail: chao0002@mc.duke.edu
Introduction
Hematopoietic cell transplantation (HCT) provides a potentially
curative treatment approach for a variety of diseases[1]. However,
HCT is associated with high incidence of morbidity and mortality.
Reducing transplant-related mortality and facilitating donor cell
engraftment are very important goals in HCT. Recombinant
granulocyte colony stimulating factor (G-CSF) is commonly used
to accelerate neutrophil recovery following HCT[2]; its effects are
limited to myeloid cells[3].
Hematopoietic stem cell (HSC) niche is a specific site in the
marrow cavity where HSCs reside and undergo self-renewal,
proliferation and differentiation[4]. HSC niche consists of
supporting cells such as osteoblasts and other stromal cells that
provide a microenvironment for HSCs, as well as molecules
produced by these cells. At least two types of HSC niches have
been identified in the bone marrow: osteoblastic/endosteal niche
and vascular endothelial niche[5,6]. The osteoblastic/endosteal
niche is thought to be the primary site for very primitive, quiescent
HSCs; while the vascular endothelial niche is the predominant site
for activated HSCs that are on their way to be released into
circulation. The detailed structure and the roles of these 2 niches
in hematopoiesis remain to be elucidated[7].
Following HCT, donor HSCs home to the marrow niches
(mainly osteoblastic niche), engraft, proliferate, and eventually
reconstitute the whole hematological and immunological reper-
toire of the recipient. HSC engraftment is limited by the
availability of niches during and after transplant when HSCs
still survive. Increasing the number of ‘‘unoccupied’’ marrow
niches enhances transplant efficiency[8,9,10]. The proliferative
status of HSCs also affects their ‘‘transplantability’’ and
engraftment. Some studies suggest that dividing HSCs are more
efficient than resting HSCs in engraft[11] and in vivo
proliferation of HSCs is crucial to hematological recovery
following transplantation[12,13], while others found that prolif-
erating HSCs displayed engraftment defect when transiting S/
G2/M phase[14,15].
An array of chemokines, growth factors, cell-surface and
adhesion molecules are required to function in concert for HSCs
to home to the niches and to engraft following HCT. In
particular, the interaction of stromal cell-derived factor-1 (SDF-1,
CXCL-12) in the marrow matrix with the CXCR4 chemokine
receptor on HSCs plays a critical role in all aspects of donor cell
reconstitution including HSC homing[16,17,18], engraftment[9]
and proliferation[14,19,20]. SDF-1 is secreted by endothelial
cells, osteoblasts and other stromal cells, and is present in marrow
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T cells and other inflammatory cells. SDF-1 is the only known
ligand for the CXCR4 receptor. Following transplantation
conditioning, the level of SDF-1 in the marrow microenviron-
ment significantly increases. The gradient difference of SDF-1
between the niche microenvironment and blood stream promotes
HSC transendothelial migration and homing to the niches[17].
Additionally, SDF-1 in the marrow extracellular matrix binds to
the CXCR4 receptors on HSCs and has dual effects: tethering
HSCs in the niches, and arresting the cycling of very primitive
HSCs[14,19,20].
AMD3100 is a highly specific and reversible antagonist of the
CXCR4 receptor[21]. AMD3100 is a bicyclam molecule with an
aromatic bridge[21], and binds with extreme specificity to CXCR4,
with contacts at amino acid positions 171, 182, 193 and 262 of
CXCR4. AMD3100 was originally studied as an agent for the
treatment of patients infected with human immunodeficiency virus
(HIV) since some strains of HIV require CXCR4 as a co-receptor
for cell entry. However, during initial clinical trials, rapid and
reversible leukocytosis was noted in human volunteers and in HIV
patients treated with AMD3100 and led the focus of AMD3100
development towards hematopoietic stem cell mobilization[22,23].
AMD3100 blockade of the SDF-1/CXCR4 interaction results in
rapid release of HSCs from marrow niches and mobilization of
HSCs into the peripheral blood[17,24,25,26,27,28]. AMD3100
was recently approved by the Food and Drug Administration
(FDA) to be used in combination with G-CSF for stem cell
mobilization in patients with non-Hodgkin’s lymphoma and
multiple myeloma.
Most of the work with AMD3100 has been exclusively on its
use as a mobilization agent[24,27,28,29,30]. We hypothesized
that post transplant administration of AMD3100 would enhance
donor cell reconstitution in myeloablative recipients. We
reasoned that AMD3100 would induce in vivo proliferation of
transplanted donor stem cells and increase additional availability
of marrow niches for donor stem cell engraftment. We report
here the effects of post transplant administration of AMD3100 on
animal survival and on donor cell engraftment in a mouse
transplantation model.
Results
1. Post transplant administration of AMD3100
significantly improves animal survival
We first examined the effects of post transplant administration
of AMD3100 on animal survival following transplantation. We
injected sorted c-Kit
+ Thy1
low Lin
2 Sca-1
+ hematopoietic stem
cells (KTLS cells) from C57BL/Ka CD45.1 Thy1.1 mice via tail
vein into lethally irradiated C57BL/6 CD45.2 Thy1.2 mice (250
KTLS cells/recipient mouse). Transplanted mice were then
injected subcutaneously with PBS control buffer or AMD3100
(5 mg/kg body weight) every Monday, Wednesday and Friday
beginning at day +2 post transplant for a total of 56 days. Animal
survival was monitored daily. We performed 3 separate sets of
experiments with 10 mice per group in each experiment. The mice
received 9.5–10.5 Gy total body irradiation. At the 10.5 Gy dose,
60% of transplanted mice receiving PBS control died within 2
weeks following transplantation. In contrast, only 13.363% (mean
6 SEM) of transplanted mice treated with AMD3100 died. The
animal survival results from our 3 separate sets of experiments are
shown in Fig. 1. These data indicate that post transplant
administration of a CXCR4 antagonist (AMD3100) significantly
improves animal survival following HCT.
2. Post transplant administration of AMD3100 selectively
enhances donor cell recovery
To determine the effects of AMD3100 on hematological
recovery, we performed blood counts weekly beginning at Day
+7. The total nucleated cells, the donor-derived cells (CD45.1
+
cells), and the recipient-origin cells (CD45.2
+ cells) in the
peripheral blood were measured using multi-color flow cytometry
analyses. As demonstrated in Fig. 2A, mice given AMD3100 had
faster nucleated cell recovery. The difference in blood nucleated
cell counts between AMD3100-treated mice and PBS-injected
control mice became statistically significant beginning at Day +36,
and was completely attributed to faster donor-derived cell recovery
(Fig. 2B). Contribution of recipient-derived cells (CD45.2
+) was
minimal (,10%) in all transplanted mice and there was no
difference in the number of recipient-derived CD45.2
+ cells
Figure 1. Post transplant administration of AMD3100 improves animal survival in a murine transplantation model. KTLS cells from
C57BL/Ka CD45.1 Thy1.1 mice were injected via tail vein into lethally irradiated C57BL/6 CD45.2 Thy1.2 mice (250 KTLS cells per mouse). Beginning 2
days after transplant (day +2), the mice were injected subcutaneously with PBS control or AMD3100 at 5 mg/kg body weight every Monday,
Wednesday, and Friday until day +56. Animal survival was monitored daily. In experiment #1 and #2, the mice received 10.5 Gy total body
irradiation using a Cesium irradiator. In experiment #3, the mice received 9.5 Gy total body irradiation. (n=10 mice in each group in each
experiment).
doi:10.1371/journal.pone.0011316.g001
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(Fig. 2C). These data demonstrate that AMD3100 selectively
augments donor derived cell reconstitution.
We next performed multi-color cell subset analyses on the blood
samples. We found that AMD3100 injection augmented the
reconstitution of not only neutrophils, but also B cells and T cells
(Fig. 2D and 2E). Again, the difference was predominantly
attributed to enhanced recovery of donor derived cells (data not
shown).Inaseparatesetofexperiment,wemeasuredthehemoglobin
concentration and platelet count at the indicated time-points. As
shown in Fig. 2F, AMD3100 administration significantly enhanced
red blood cell recovery. Although the platelet count was higher in
AMD3100-treated mice at day +43 post transplantation, the
difference was not statistically significant (Fig. 2G). This may be
because the platelet count had reached normal levels in both groups
at the time the platelet counts were measured. Nevertheless, these
data suggest that AMD3100 administration enhances reconstitution
of all hematological lineages.
3. Post transplant administration of AMD3100 reduces
pro-inflammatory cytokine production
It is noteworthy that there is a temporal difference between animal
survival benefit and the blood hematological recovery seen in
AMD3100-treated mice. The reduced mortality seen in AMD3100-
Figure2.PosttransplantadministrationofAMD3100selectivelyenhancesreconstitutionofalldonor-derivedhematologicallineagesof
cells. KTLS cells from C57BL/Ka CD45.1 Thy1.1 mice were injected via tail vein into lethally irradiated C57BL/6 CD45.2 Thy1.2 mice (250 KTLS cells per
mouse). Beginning 2 days after transplant (day +2), the mice were injected subcutaneously with PBS control or AMD3100 at 5 mg/kg body weight every
Monday, Wednesday, and Friday until day +56. Hematologicalrecovery and cell subset analyses were determined at thetime pointsindicated, as described
in Methods. The graphs are representative of3 separatesets ofexperiments with 10mice in eachgroup in eachexperiment.A: Blood nucleated cell counts
(/ml) (normal range of mouse white cell counts: 1.8–10.7610
3/ml ) .B :D o n o r - d e r i v e dC D 4 5 . 1
+ cell counts (/ml). C: Blood recipient origin CD45.2
+ cell counts
(/ml). D: Blood CD3
+ Tc e l lc o u n t s( / ml). E: Blood B220
+ B cell counts (/ml). F: Hemoglobin concentration (g/dl) (normal range of mouse hemoglobin level: 11–
15.1 g/dl). G: Blood platelet counts (610
6/ml) (normal range of mouse platelet count: 592–2972610
6/ml). *: p,0.05.
doi:10.1371/journal.pone.0011316.g002
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blood cell count differences were apparent between AMD3100-
treated and PBS-injected mice.One possibleexplanationforthistime
gap could be that AMD3100 promotes earlier hematopoietic
progenitor recovery. To determine whether post transplant admin-
istration of AMD3100 would affect hematopoietic progenitor cell
recovery,we measured CFUs-spleen at day +9. As shown in Fig. 3A,
AMD3100-treated mice demonstrated a trend to higher number of
CFUs-spleen compared to PBS- injected control mice.
Another possible mechanism may be related to AMD3100
mediated- inhibition of a cytokine storm. Transplant preparative
conditioning induces massive cell death and tissue damage,
resulting in a dramatic increase in the levels of secreted
chemokines, cytokines and proteolytic enzymes[16]. This massive
release of cytokines/chemokines (a ‘‘cytokine storm’’) exacerbates
inflammation and vascular/tissue injuries, and leads to multi-
organ toxicities. CXCR4 plays an important role in the cytokine
storm by recruiting inflammatory cells to the injury sites[31,32].
We reasoned that post transplant administration of AMD3100
would attenuate the cytokine storm, and hence reduce multi-organ
toxicities. We measured a total of 23 serum cytokines at Day +7
post transplantation (Fig.3B). We found that post transplant
Figure 3. Post transplant administration of AMD3100 increases CFUs-spleen and reduces cytokine, chemokine, and growth factor
levels. A: CFUs-spleen assay. Lethally irradiated CD45.2 mice (10.5 Gy) were injected with whole marrow cells from CD45.1 mice (1610
5 marrow cells
per mouse). The recipient mice were injected subcutaneously with PBS buffer or AMD3100 at 5 mg/kg every other day beginning at day +2. At day
+9, the mice were sacrificed and CFUs-spleen measured (n=5–10 mice per group). B: Plasma cytokine/chemokine measurement. Lethally irradiated
CD45.2 mice (10.5 Gy) were injected with sorted KTLS stem cell from CD45.1 mice (7000 KTLS cells per mouse). The recipient mice were injected
subcutaneously with PBS buffer or AMD3100 at 5 mg/kg every other day beginning at day +2. The mice were bled at Day +7 and plasma prepared.
Plasma cytokines and chemokines (pg/ml) were measured as per manufacturer’s instruction (Bioplex, Bio-Rad Laboratories) (n=5 mice per group). G-
CSF level was shown in a separate panel. C: 9 cytokines/chemokines that were significantly reduced in AMD3100-treated mice. D: Survival rate in
lethally irradiated mice without HCT. CD45.2 mice were lethally irradiated (10.5 Gy) but not transplanted with HSCs. The mice were then administered
subcutaneously with PBS or AMD3100 at 5 mg/kg every other day beginning at day +2 post irradiation until the end of experiments. Animal survival
was monitored daily (data representative of 3 separate sets of experiments with 10 mice in each group of each experiment).
doi:10.1371/journal.pone.0011316.g003
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levels of 9 pro-inflammatory cytokines/chemokines (IL-1, IL-3, IL-
12, IL-17, tissue necrosis factor-a, GM-CSF, interferon-l,
macrophage-inhibitory protein-1 and eotaxin) (Fig. 3C).
We next examined if AMD3100 could protect mice from lethal
irradiation without the need for HCT. Lethally irradiated C57BL/
6 CD45.2 Thy1.2 mice (10.5 Gy) were given AMD3100 at 5 mg/
kg body weight either at day 2 post irradiation and then every
other day until the death of mice or within one hour post
irradiation and then daily for 5 days. As shown in Fig. 3D,
without HSC transplant, all the irradiated mice died by day 17
and there were no significant differences in animal survival
between AMD3100-treated mice and PBS-injected mice. These
data imply that the effects of AMD3100 on HSCs may indeed play
a critical role in improving animal survival.
4. Post transplant administration of AMD3100 enhances
donor marrow cell engraftment
To further investigate the effects of AMD3100 on marrow
hematopoietic progenitor/stem cell recovery, we administered the
last AMD3100 injection at day +56 and sacrificed the mice at day
+65 and harvested bone marrow for CFU-GM assay, histopath-
ological examination and flow cytometry analyses. Compared to
PBS-injected- mock control mice, mice receiving AMD3100
injection had increased frequencies of CFUs-GM (represented as
colony numbers/10
5 marrow nucleated cells, Fig. 4A) and had a
Figure 4. Post transplant administration of AMD3100 enhances donor cell marrow engraftment. The mice as described in Fig. 1 were
sacrificed at Day +65 post transplantation, and 2 femurs and 2 tibias were harvested and processed and analyzed as described in Methods. A: CFU-GM
assay. CFU-GM colonies were measured in individual mice using MethoCultH GF 3434 mouse colony-forming cell assay. B: Histology. Bone marrow
from individual mouse was examined by microscopy (4X: top panel and 100X: bottom panel) after decalcification and H/E staining. Trabecular bony
structure, osteoblasts, hematopoietic cells, sinusoid vessels and acellular areas filled with lipid droplets were indicated. Normal mice did not receive
transplant or AMD3100 injection. C: Total nucleated cell number from 1 femur and 1 tibia. D: Donor-derived CD45.1
+ KLS stem cell number from 1
femur and 1 tibia of individual mouse. E: Recipient-origin CD45.2
+ KLS stem cell number from 1 femur and 1 tibia of individual mouse. *: p,0.05.
doi:10.1371/journal.pone.0011316.g004
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trabecular bony structures, osteoblasts and sinusoid vessels were
preserved, the hematopoietic cell components were significantly
expanded in AMD3100-treated mice. Furthermore, 3 of 4 PBS-
injected- mock control mice had large areas filled with lipid
droplets and devoid of cells (Fig. 4B, indicated as stars). These
large acellular areas are commonly associated with radiation[33].
In contrast, the large areas (fat droplets) were not found in any of
the mice receiving AMD3100 (8 of 8 mice) (Fig. 4B). In addition,
we collected one femur and one tibia from each mouse and
measured total nucleated marrow cells, total donor-derived
CD45.1
+ KLS hematopoietic stem cells (c-kit
+ Lin
2 Sca-1
+ cells)
and recipient-origin CD45.2
+ KLS cells. As shown in Fig. 4C and
4D, AMD3100-treated mice had significantly higher numbers of
total marrow nucleated cells and total donor-derived CD45.1
+
KLS cells per one femur and one tibia (One femur plus one tibia
account for ,7.5% of whole body marrow cells[34]). There was
no difference in the recipient- derived CD45.2
+ KLS cell (Fig. 4E).
These data again suggest that post transplant administration of
AMD3100 selectively enhances donor cell marrow engraftment.
The total nucleated cells, the donor-derived CD45.1
+ KLS cells,
and the recipient-origin CD45.2
+ KLS cells in the spleen were not
significantly different between AMD3100-treated mice and PBS-
injected mock mice (data not shown).
5. Post transplant administration of AMD3100 mobilizes
recipient’s residual stem cells, increasing marrow niche
availability
We examined the mechanisms by which AMD3100 selectively
enhances donor cell engraftment. We performed additional
experiments to investigate the effects of post transplant
AMD3100 administration on the mobilization of recipient HSCs
and the homing of donor HSCs. Lethally irradiated C57BL/6
CD45.2 Thy1.2 mice (10.5 Gy) were injected via tail vein with
sorted KTLS hematopoietic stem cells (2500 cells/mouse) ob-
tained from C57BL/Ka CD45.1 Thy1.1 donor mice. At 48 hours
after transplantation, recipient mice were injected subcutaneously
with a single dose of AMD3100 at 5 mg/kg or PBS control.
Twenty-four hours after this injection, the mice were sacrificed, 2
femurs and the spleen harvested, and recipient-originated
CD45.2
+ KLS and donor-derived CD45.1
+ KLS stem cells
measured. As shown in Fig. 5A, the mice receiving AMD3100
injection had significantly lower number of recipient CD45.2
+
KLS stem cells in the marrow, indicating that AMD3100
mobilizes the recipient stem cells from the marrow. In our 2
separate sets of experiments in which lethally irradiated C57Bl/6
CD45.2 Thy 1.2 mice received sorted CD45.1
+ hematopoietic
cells (2500 KTLS cells) and 2 femurs harvested at 72 hrs post
transplantation, we were not able to measure donor derived
CD45.1
+ KLS cells in the marrow samples using flow cytometry
analysis because of the limited number of KTLS cells infused.
Interestingly however, we found that AMD3100-treated mice had
significantly higher number of marrow derived CFU-GM and
BFU-E, indicating enhanced donor marrow engraftment (Fig. 5B).
Furthermore, although the number of recipient-origin KLS stem
cells in the spleen was similar in both groups (Fig. 5C), the
AMD3100-treated mice had significantly higher number of donor
derived CD45.1
+ KLS stem cells in the spleen (6.461.5%)
compared to PBS control mice (0.9660.36%; p,0.01) (Fig. 5D).
These results suggest that AMD3100 administered shortly after
transplantation increases donor stem cell homing efficiency by
expanding the available marrow niches. The available niches are
likely expanded as a consequence of AMD3100-induced mobili-
zation of recipient’s residual bone marrow cells from marrow
niches, allowing a competitive advantage for the healthy donor
cells.
To determine if prolonged administration of AMD3100 could
still acutely mobilize hematopoietic stem/progenitor cells, we
measured colony-forming units and white blood cell counts in
peripheral blood 4 hours after giving AMD3100 in transplanted
mice that had received AMD3100 every other day beginning at
day +2 for 60 days. As shown in Fig. 5E, AMD3100 given every
other day for 60 days mobilized hematopoietic progenitor cells at a
level comparable to those in naı ¨ve mice receiving the first dose of
AMD3100 injection.
6. Post transplant administration of AMD3100 increases
donor cell division
The proliferative status of HSCs affects their ability to
engraft[11,14,19] and the speed of hematological recovery[12,13].
Mobilized HSCs are innately more proliferative[35]. Furthermore,
binding of SDF-1 to CXCR4 receptor inhibits the division of
primitive HSC cells[14,19,20]. To determine whether blocking
CXCR4 receptor with AMD3100 could promote in vivo cycling of
donor HSCs, we injected 5-(and -6)-carboxyfluorescein diacetate
succinimidyl ester (CFSE) - labeled donor KTLS cells (Fig. 6A)
and measured their division status at Day +7 post transplant
(Fig. 6A). With each cell division, the CFSE is diluted and
fluorescence intensity decreases in a step-wise fashion. Compared
to control mice, AMD3100- injected mice had reduced percentage
of cells in higher intensity peaks (Fig. 6A, lower panels, dot
plots and histograms), indicating more rounds of cell division.
Additionally, AMD3100-treated mice had much higher number of
donor derived CD45.1
+ cells compared to PBS-injected mice
(Fig. 6A: total CD45.1
+ cells). To rule out direct stimulating
effects of AMD3100, we measured
3H incorporation in vitro in
marrow cells co-cultured with various concentrations of
AMD3100 or G-CSF. The proliferating effect of AMD3100 on
marrow cells was minimal - approximately 100-1000 fold less than
that induced by G-CSF (Fig. 6B).
7. Post transplant administration of AMD3100 maintains
hematopoietic stem cell’s long-term repopulating
capacity
The ability of AMD3100 to increase in vivo donor cell division
and proliferation raises the concern that prolonged post transplant
administration of AMD3100 may exhaust stem cell pool. To
determine the effects of AMD3100 on HSC self-renewing and
long-term repopulating capacities, we performed secondary
transplant experiments (Fig. 7). We harvested bone marrow cells
from transplanted C57BL/6 CD45.2 Thy1.2 recipient mice at
day +65 (i.e., primary transplant recipients). These primary
transplanted mice received HSCs from donor C57BL/6
CD45.1 mice and were given post transplant administration of
AMD3100 at 5 mg/kg body weight or PBS subcutaneously every
other day from day +2t o+60. The bone marrow cells from
primary transplant recipients were then injected intravenously into
lethally irradiated C57BL/6 CD45.2 Thy1.2 mice (i.e., secondary
transplant recipients). The whole marrow cells harvested from 1
femur and 2 tibias of one primary mouse were injected into one
secondary mouse (one to one matched transplant). At ,7 weeks
after transplant, the secondary C57BL/6 CD45.2 Thy1.2
transplanted recipient mice were bled and the CD45.1
+ donor
cell contribution in peripheral granulocytes determined. In the
secondary transplant recipients that received bone marrow from
AMD3100-treated primary transplant mice, 79614% blood
granulocytes were derived from CD45.1
+ donor cells, compared
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injected primary transplant mice (Fig. 7; p.0.05). These data
demonstrated that post transplant administration of AMD3100
preserved the long-term repopulating HSC pool.
Discussion
In our current study, we utilized a specific and reversible
CXCR4 antagonist to explore the biological roles of SDF-1/
CXCR4 interaction in hematopoiesis and HSC engraftment
following HCT. Unlike other chemokines, SDF-1 binds to one
single chemokine receptor, CXCR4, which itself is not recognized
by any other ligands. CXCR4 knockout mice die in utero and are
defective in vascular development, hematopoiesis and cardiogen-
esis[36]. AMD3100 selectively antagonizes CXCR4 receptor and
does not bind to other chemokine receptors. The extreme
specificity of AMD3100 makes it a very useful and powerful tool
to be used to investigate the role of SDF-1/CXCR4 in HSC
engraftment and reconstitution. AMD3100 has a very short half-
life, and is rapidly eliminated with an estimated distribution half-
life of 0.3 hours and a terminal half-life of 5.3 hours[37]. In our
current study, AMD3100 was given every other day. Our results
suggest that even a short period of transient CXCR4 blockade
could have dramatic impact on animal survival and on HSC
engraftment following HCT.
One of our most striking findings of the study was that
AMD3100 given after transplant significantly improves survival in
lethally irradiated mice transplanted with limited number of
hematopoietic stem cells. Interestingly, the recovery of peripheral
blood count appears to lag behind the survival benefit (Fig. 1 and
2). It is not uncommon to see a temporal discrepancy between
survival benefit and peripheral blood cell count in transplantation
animal models. For example, Chen et al transplanted T cell-
depleted bone marrow cells into lethally irradiated allogeneic mice
and observed survival benefit at 2 weeks when the peripheral
blood counts were still depressed[38]. Most recently, we also
observed survival benefit in transplanted mice treated with growth
hormone at a time when the peripheral blood count just started to
recover[39]. There are 2 possible explanations for this time gap
between survival benefit and peripheral blood cell count recovery.
First, it is possible that the threshold for peripheral blood count to
achieve survival benefit may be low and a slight increase in blood
counts may have dramatic impacts on animal survival. Secondly,
the peripheral blood count may underestimate the degree and the
speed of hematological recovery. In the early recovery phase
following transplantation, bone marrow, spleen and other organs
are the predominant sites for hematopoiesis.
The differences in blood nucleated cell counts between
AMD3100-treated mice and PBS- injected mice became signifi-
cant at ,5 weeks after transplantation (Fig. 2). The slow
peripheral blood hematological recovery and the delayed effects
of AMD3100 on hematological reconstitution are likely due to
very limited number of KTLS stem cells transplanted in these
mice. The mice received approximately 250 KTLS stem cell per
mouse in our study. Using a limiting dilution assay, Uchida et al
found that engraftment kinetics depended on the number of
transplanted HSCs and that the most rapid engraftment occurred
when the mice received $5000 KTLS cells per mouse[40].
Compared to B cell recovery, AMD3100 had less effect on T cell
reconstitution (Fig. 2). This discrepancy in the effects of
AMD3100 on T and B cell reconstitution results from the
different mechanisms of B-cell and T cell regenerations following
transplantation[41]. B cell recovery after transplantation recapit-
ulates normal B-cell ontogeny and derives directly from bone
marrow lymphoid progenitors. In contrast, T cell reconstitution
occurs through both thymic and extrathymic pathways. The
contribution of bone marrow lymphoid progenitor cells in T cell
reconstitution is limited and highly variable.
Our study suggests that augmented hematological recovery and
reduced inflammatory cytokine storm both contribute to the
survival benefit observed in AMD3100-treated mice. However, the
extent and the relative contribution of each of these 2 mechanisms
to animal survival remain to be elucidated. Although our data
suggested that hematopoietic stem cells are essential in rescuing
these mice from lethal irradiation (Fig. 3D), it is possible that
AMD3100 enhances hematological recovery by altering the levels
of cytokines/chemokines in marrow microenvironment. Recent
studies found that many cytokines and chemokines in the niche
microenvironment are involved in hematopoiesis following
transplantation[5,6]. Further dissection of the benefit of these 2
mechanisms in survival will require further studies including the
use of knockout mice such as MyD88 mice (toll-like receptor
knockout mice that fail to elicit a cytokine storm)[42].
Our results demonstrate that the CXCR4 chemokine receptor is
involved in transplant-related cytokine storm and subsequent
multi-organ toxicity. Blocking CXCR4 with AMD3100 improves
animal survival. In addition to HSCs, CXCR4 is also expressed on
T cells, B cells, macrophages, dendritic cells, eosinophils,
fibroblasts and other inflammatory cells. SDF-1/CXCR4 interac-
tion recruits inflammatory cells to the injury site, exacerbates
inflammation and thus plays an important role in the pathogenesis
of autoimmune diseases[31,32], idiopathic lung fibrosis[43],
bleomycin-induced lung injury[44], and possibly in acute graft
versus host disease[45]. Consistent with the important role of
CXCR4 in these disease processes, blocking CXCR4 with
AMD3100 attenuates autoimmune responses[31,32] and improves
lung functions[46]. The observation of the decrease in the
inflammatory cytokines and improved animal survival by
Figure 5. Post transplant administration of AMD3100 mobilizes recipient residual HSCs, increasing marrow niche availability. Lethally
irradiated C57BL/6 CD45.2 Thy1.2 mice (10.5 Gy) were injected via tail vein with sorted KTLS hematopoietic stem cells (2500 cells/mouse) obtained from
C57BL/Ka Thy1.1 donor mice. At 48 hours after transplantation, recipient mice were injected subq with a single dose of AMD3100 at 5 mg/kg or PBS
control. Twenty-four hours after this injection, the mice were sacrificed, and the 2 femurs and the spleen were harvested. Recipient-origin stem cells
(CD45.2
+ KLS cells) and donor derived stem cells (CD45.1
+ KLS cells) in the spleen and in the marrow were determined. Marrow CFUs-GM and Bursting
forming units of erythrocytes (BFUs-E) were measured using MethocultH GF 3434 (1610
5 cells/dish, triplicate dishes per individual mouse). Percent donor
stem cell homing efficiency to the spleen was calculated by dividing the absolute number of CD45.1
+ KTLS stem cells in the recipient’s spleen by the
number of injected KTLS stem cells. The graphs are representative of 2 separate sets of experiments with 5–10 mice in each group of each experiment. A:
total number of recipient CD45.2
+ KLS stem cells in 2 femurs. B: marrow CFU-GM and BFU-E assay (numbers of donor CFU-GM and BFU-E/3610
5 marrow
cells). C: total number of recipient stem cells in the spleen. D: % donor stem cell homing efficiency in the spleen. E: Measurement of hematopoietic stem/
progenitor cell mobilization after prolonged AMD3100 administration. Transplanted mice that were given AMD3100 at 5 mg/kg body weight or PBS
subcutaneously every other day beginning at day +2 for 60 days and naı ¨ve normal control mice were injected with AMD3100 subcutaneously at 5 mg/kg
bodyweight orPBS.Bloodsampleswerecollectedimmediately priortotheinjectionand4 hours after injection, andcolony-formingunitsandwhiteblood
cell counts determined. Colony-forming units were represented as colony numbers/30 ml blood (n=5 in each group. Open bar: before AMD3100 injection.
Filled bar: 4 hours after AMD3100 injection). *: p,0.05. NS: not statistically significant.
doi:10.1371/journal.pone.0011316.g005
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PLoS ONE | www.plosone.org 8 June 2010 | Volume 5 | Issue 6 | e11316Figure 6. Post transplant administration of AMD3100 increase donor cell division. A: In vivo cell division measurement. CD45.1
+ KTLS cells
were labeled with CFSE and injected into lethally irradiated C57BL/6 CD45.2 Thy1.2 mice (7610
3 KTLS cells/mouse). The 2 panels on the left showed
the sorted CFSE-labeled KTLS cells prior to injection to recipient mice. The recipient mice were treated with AMD3100 at 5 mg/kg or PBS every other
day beginning at day +2. The mice were sacrificed at day +7 and bone marrow cells measured for CFSE intensity (The 4 panels on the right. Top 2
panels: recipient mice treated with PBS control; Lower 2 panels: recipient mice treated with AMD3100). The CFSE intensity was gated on CD45.1
+
donor derived cell population (n=5 mice in each group). B: In vitro marrow cell proliferation responses to AMD3100 or G-CSF. Marrow cells
(5610
5/well) were cultured with various concentrations of AMD3100 or recombinant G-CSF, and [
3H] thymidine incorporation was measured (three
separate sets of experiments with triplicates in each experiment).
doi:10.1371/journal.pone.0011316.g006
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more broadly for any toxic preparatory regimen and for other
inflammatory disease processes.
Our present studies demonstrate that post transplant adminis-
tration of AMD3100 selectively enhances donor hematopoietic cell
engraftment in a myeloablative setting. Our data suggest that there
are three related mechanisms involved in this selective enhance-
ment of donor hematopoietic cell reconstitution by post transplant
administration of AMD3100 (Fig. 8). The first is that there is
mobilization of residual radioresistant host HSCs and thus further
opening of hematopoietic niches and a selective advantage for
engraftment of the healthy donor HSCs. Secondly, AMD3100
reverses the proliferation-inhibitory effect of SDF-1. SDF-1 arrests
the cycling of primitive HSCs[14,19,20] and thus blocking the
SDF-1/CXCR4 interaction results in proliferation/expansion of
primitive HSCs. Thirdly, mobilized HSCs are innately more
proliferative than HSCs in the niches[35]. Mobilizing the donor
HSCs results in more cell division, further increasing the numbers
of donor derived marrow cells. Compared to donor HSCs,
recipient residual HSCs likely have survival disadvantage and/or
impaired engraftment/proliferation capacity due to the insults
from total body irradiation, resulting in selective engraftment and
expansion of donor hematopoietic cells.
The number of available niches determines the degree of donor
HSC engraftment. In non-ablated mice, AMD3100 can mobilize
recipient HSCs, vacate niches and improve donor HSC
engraftment[9]. Our data suggest that even in a myeloablative
setting, post transplant administration of AMD3100 could further
increase the availability of niches and/or keep the marrow niches
open when given repeatedly. The restoration and expansion of
niches occurs soon after irradiation and is evident at 48 hours post
irradiation[47]. Salter et al recently found that infusion of
endothelial progenitor cells alone could rescue mice from total
body irradiation, suggesting that some host HSCs could survive
total body irradiation[48]. Transplant preparative conditioning
such as total body irradiation increases the levels of SDF-1 in the
marrow. SDF-1 arrests the cycling of very primitive HSCs[14,19].
In contrast, administration of an SDF-1 antagonist enhances HSC
engraftment in vivo[9,14]. Furthermore, Passegue et al have
shown that mobilized HSCs are more proliferative than HSCs in
the niches[35]. HSC expansion is crucial to hematological
recovery following transplantation[12,13]. This would also explain
the enhancement of donor cell engraftment and recovery seen
with repeated administration of AMD3100 following HCT.
We administered AMD3100 at day +2 post transplant and
continued the injection every other day. AMD3100 blockade of
CXCR4 is reversible and the half-life of AMD3100 is short
(terminal half life of ,5 hours). Thus, it is very likely that the
48 hour interval between AMD3100 injections could allow HSCs
to mobilize from ‘‘quiescent-storage’’ niche, enter the cell cycle to
expand, and then return to their marrow niches and become
quiescent again. This repeated, periodic and pulsed release of
HSCs followed by expansion and return to quiescent state may be
important in the enhanced hematological recovery observed in our
study. Although the effects of persistent and continuous blockade
of CXCR4 on hematopoiesis following transplant remain to be
elucidated, there is a concern that permanent blockade of CXCR4
might actually impair hematopoiesis. Permanent blockage of
CXCR4 may result in the failure of proliferating HSCs to return
to ‘‘quiescent-storage’’ niches, leading to increased rate of cell
death and impaired hematological recovery.
In our current study, AMD3100 was given every other day for
approximately 60 days. We are currently testing various
administration regimens including shorter duration of treatment
and the use of AMD3100 as part of conditioning regimens. Our
preliminary study indicated that shorter duration of treatment
such as every other day for 30 days was as effective as 60 day
administration (unpublished data).
There were several conflicting articles reporting the effects of
SDF-1 and CXCR4 antibody on hematopoiesis after trans-
plant[14,17,19,20,49,50]. For example, Peled et al reported
reduced homing and impaired engraftment with treatment of
graft cells with CXCR4-blocking antibody[17], while Plett et al
suggested increased repopulating potential of treated CD34
+
cells[50]. One study suggested that in vivo administration of SDF-
1 was accompanied by enhanced transplantability of human
CD34
+ cells in NOD/SCID mice[20], whereas others reported
increased engraftment with SDF-1 antagonist[9,14]. These
discrepancies are likely related to the differences in transplant
models, the proliferative status of the grafts, the specificities of
CXCR4 antibodies/antagonists and even the concentration of
SDF-1. SDF-1 exhibits ‘‘concentration-dependent bifunctional
effects’’, i.e., SDF-1 can attract or repel cells at different
concentrations[50]. Furthermore, AMD3100 may act as CXCR4
partial agonist at high concentration[51]. Our findings are similar
to those reported by Plett et al[50], Chen et al[9], Bowie et al[14],
and Abraham et al[49] using a novel CXCR4 antagonist (4F-
Figure 7. Post transplant administration of AMD3100 main-
tains HSC’s long-term repopulating capacity. Bone marrow cells
from transplanted C57BL/6 CD45.2 Thy1.2 recipient mice (i.e., primary
transplant recipients) were harvested at day +65, and injected
intravenously into lethally irradiated C57BL/6 CD45.2 Thy1.2 mice (i.e.,
secondary transplant recipients) (one to one matched transplant). The
primary transplanted mice received HSCs from donor C57BL/6 CD45.1
mice and were given post transplant administration of AMD3100 at
5 mg/kg subcutaneously every other day from day +2t o+60
(AMD3100-primary) or PBS (PBS-primary). At ,7 weeks after transplant,
the secondary C57BL/6 CD45.2 Thy1.2 transplanted recipient mice were
bled and the CD45.1
+ donor cell contribution in peripheral granulocytes
determined. (n=6 in each group).
doi:10.1371/journal.pone.0011316.g007
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recovery of marrow after transplantation with the CXCR4
antagonist 4F-benzoyl-TN14003[49].
The overall effects of the blockage of CXCR4/SDF-1 with
AMD3100 on hematopoiesis are outlined in Fig. 8. Additionally,
AMD3100 could affect molecular components of niche microen-
vironment such as cytokines, chemokines, neurotransmitters, and
oxidative status that are crucial to the homing, proliferation and
mobilization of HSCs. Our results indicate that AMD3100
promotes recovery of all donor cell lineages, including myeloid
cells, T and B lymphocytes, erythrocytes and platelets. The data
suggest that AMD3100 enhances engraftment of multipotent
primitive HSCs. Furthermore, as shown in Fig. 2 and 4, the total
blood counts and marrow KLS stem cells in AMD3100-treated
mice at day +65 were significantly higher than those in PBS-
injected control mice. Moreover, using secondary transplant
model, we found that prolonged post transplant administration
of AMD3100 did not adversely affect the long-term engraftment of
primitive HSCs (Fig. 7).
Our current study provides important insights into the roles of
SDF-1/CXCR4 interaction in transplant-related mortality and in
hematopoiesis following HCT. Our study suggests that blocking
SDF-1/CXCR4 interaction with CXCR4 antagonist has many
important ramifications not only in clinical HSC transplantation, but
also potentially in other clinical settings that involve exaggerated
inflammatory responses. Since AMD3100 is FDA approved for
mobilization of HSCs, the translational potential of this agent is
significant. Its use to enhance engraftment and decrease the toxicity
would be especially important in clinical setting such as cord blood
transplantation where engraftment remains a problem. AMD3100
can also be used routinely in any myeloablative allogeneic
transplantation to ensure robust donor cell engraftment. Our studies
indicate that post transplant administration of AMD3100 is a new
approach for enhancing hematological recovery and reducing
transplant-related mortality in HCT.
Methods
Animals
Eight to twelve week old C57BL/6, CD45.2, Thy1.2 (H2
b,
termed ‘‘CD45.2 mice’’) mice were purchased from the Jackson
Laboratories (Bar Harbor, ME). C57BL/Ka, CD45.1, Thy1.1
mice (H2
b, termed
‘‘CD45.1 mice’’) were bred and maintained in
our specific pathogen-free animal facility. Studies were performed
in accordance with Duke University Institutional Animal Care and
Use Committee-approved procedures.
Antibodies and reagents
AMD3100 used in our first 2 sets of in vivo experiments was
purchased from Sigma (St Louis, MO). AMD3100 (Plerixafor,
Mozobil
TM, Genzyme Corp.) provided by Genzyme Corp under a
research agreement was used in our third set of in vivo experiment
and in all other studies, including stem cell homing studies,
cytokine studies and in vivo proliferation experiments. Antibodies
for phenotypic analyses included: R-phycoerythrin (PE)-conjugat-
ed anti-CD45.1 (clone A20); FITC- conjugated anti-CD45.2
(clone 104); APC-Cy7-labeled anti-CD45.2; APC-conjugated anti-
CD3 (clone 145-2C11); APC-Cy7-labeled anti mouse CD4 (L3T4,
clone GK1.5); PE-Cy7 labeled anti mouse CD8a (Ly-2, clone 53–
6.7); Biotin conjugated anti mouse Gr-1 (clone RB6-8C5), and
APC conjugated anti mouse CD117 (c-kit, clone 2B8). All of these
antibodies were from BD Pharmingen (San Diego, CA). Tricolor-
conjugated anti mouse CD45R (B220) was from Caltag (South
San Francisco, CA); and PE-Cy7 conjugated anti mouse Sca-1
(clone D7) was from eBiosciences (San Diego, CA). Antibodies
used for purification of hematopoietic stem cells are noted below.
Murine hematopoietic stem cell transplantation
Donor mouse c-Kit
+Thy1.1
lowLin
2/lowSca-1
+ hematopietic
stem cells (KTLS cells) were obtained from CD45.1 mice as
Figure 8. Schematic diagram of AMD3100’s mechanisms of action. Post transplant administration of AMD3100 likely has 3 effects. 1.
AMD3100 mobilizes residual recipient’s radioresistant HSCs (indicated as red circle), thus freeing up more niches for healthy donor HSCs (indicateda s
purple circles) to engraft. This is supported by Fig. 5. 2. AMD3100 relieves the inhibitory effect of SDF-1 on primitive HSCs, allowing for engrafted
HSCs to proliferate. 3. AMD3100 mobilizes engrafted donor HSCs and mobilized HSCs are more active and more proliferative. Effects 2 and 3 are
supported by Fig. 6. Recipient HSCs after irradiation likely have survival disadvantage compared to donor HSCs. The end result is selective
engraftment and expansion of donor hematopoietic cells.
doi:10.1371/journal.pone.0011316.g008
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CD45.1 mice were first depleted of red blood cells using ACK
solution (0.15 M ammonium and 0.01 M potassium carbonate).
Red cell-depleted bone marrow cells were then enriched for c-Kit
+
cells by positive selection using purified anti-c-Kit antibody (clone
ACK45; BD Pharmingen) followed by incubation with goat anti-
rat magnetic beads from Miltenyi Biotec. C-Kit-enriched bone
marrow cells were subsequently stained with a cocktail of primary
monoclonal antibodies consisting of biotin-conjugated anti-CD3
(clone 145-2C11), anti-CD4 (clone RM4-5), anti-CD5 (clone 53–
7.3), anti-CD8a (clone 53–6.7), anti-CD11b (clone M1/70), anti-
B220 (clone RA3-6B2), anti-Gr-1 (clone RB6-8C5), and anti-
TER-119 (clone TER-119); FITC-conjugated anti-Thy1.1 (clone
OX-7); PE-conjugated anti-Sca-1 (clone E13-161.7); and allophy-
cocyanin-conjugated anti-c-Kit (clone 2B8); followed by secondary
staining with streptavidin-Cy-Chrome (all purchased from BD
Pharmingen). Propidium iodide (1 mg/mL; Sigma, St Louis, MO)
was added to the cell suspension to exclude dead cells before cell
sorting. The stained samples were sorted for c-Kit
+Thy1.1
low
Lin
2/lowSca-1
+ hematopoietic stem cells (KTLS) cells using a dual
laser fluorescence activated cell sorter (FACS) Vantage SE (Becton
Dickinson, San Jose, CA).
The recipient CD45.2 mice were given total body irradiation
using a cesium irradiator. The mice received 10.5 Gy irradiation
in the first 2 sets of experiments and 9.5 Gy in the third set of
experiment. Within 4 hours after irradiation, the CD45.2 mice
were injected via tail vein with the sorted KTLS hematopoietic
stem cells (250 KTLS cells per mouse).
AMD3100 administration
The transplanted mice were injected subcutaneously with PBS
mock control or AMD3100 at 5 mg/Kg body weight in a volume
of 100 ml every Monday, Wednesday and Friday beginning at day
+2 post transplant until day +56. Animal survival was monitored
daily.
Measurement of hematological recovery
To determine peripheral blood hematological recovery and to
quantify various cell subsets, blood samples were obtained using
heparinized capillary tubes at the indicated time points. Fifty
micro-liters of blood were stained with monoclonal antibodies for
15 minutes at room temperature. The stained whole-blood
samples were then processed in BD FACS
TM Lysing solution to
lyse red blood cells. Flow-Count fluorospheres (50 mL; Beckman-
Coulter) were added before flow cytometric analysis. Stained cells
were analyzed using BD FACSCanto
TM (BD Biosciences, San
Jose, CA). The absolute counts were calculated using the following
formula: Absolute count (cells/mL blood) = (Total number of cells
counted/Total number of fluorospheres counted) x Flow-Count
fluorosphere concentration. Hemoglobin concentration and plate-
let counts were measured using a HemavetH counter (Drew
Scientific, Inc, Dallas, Texas) as per manufacturer’s instruction.
To determine marrow and spleen hematopoietic stem/progen-
itor cell recovery, the transplanted recipient mice were sacrificed at
day +65, and 2 femurs, 2 tibias and the spleen were harvested.
Several analyses were performed including histological examina-
tion, nucleated marrow cell counts, colony forming unit assay
(CFUs), and stem cell quantification. One femur and one tibia
were used for histological examination. The femur and tibia were
fixed in 10% buffered neutral formalin (VWR International, West
Chester, PA). Bone was decalcified, stained with H&E, and
examined by microscopy. The other femur and tibia marrow
cavities were flushed, and marrow cells were resuspended in 4 ml
of RPMI1640 containing 10% fetal calf sera. The total nucleated
cells of the femur and the tibia were counted using the HemavetH
counter. To determine the frequency of colony forming units-
granulocytes and megakaryocytes (CFUs-GM), marrow cells from
individual mice were plated in MethocultH GF 3434 (1610
5 cells/
dish, triplicate dishes per individual mouse) as per manufacturer’s
instruction (StemCell Technology, Vancouver, Canada). The
number of CFUs-GM was counted at day 12. To determine the
numbers of donor- derived CD45.1
+ c-kit
+ Lin
2 Sca-1
+ (KLS)
hematopoietic stem cells and recipient-origin CD45.2
+ KLS cells,
the marrow cell suspension was stained with PE-conjugated
CD45.1 antibody, FITC-conjugated CD45.2, APC-labeled c-Kit
antibody, PE-Cy5 conjugated Sca-1 and biotin-conjugated anti-
CD3 (clone 145-2C11), anti-CD4 (clone RM4-5), anti-CD5 (clone
53-7.3), anti-CD8a (clone 53-6.7), anti-CD11b (clone M1/70),
anti-B220 (clone RA3-6B2), anti-Gr-1 (clone RB6-8C5), and anti-
TER-119 (clone TER-119); followed by secondary staining with
streptavidin-Cy-Chrome. The absolute KLS stem cell number in
one femur and one tibia was calculated multiplying total number
of nucleated marrow cells with % KLS cells on flow cytometry
analysis. The absolute cell numbers of recipient-origin stem cells
(CD45.2
+ KLS cells) and donor derived stem cells (CD45.1
+ KLS
cells) in the spleen were similarly determined.
Cytokines/chemokines measurement
Lethally irradiated CD45.2 mice were transplanted with KTLS
cells and treated with PBS or AMD3100 as described above. At
day +7 post transplantation, the mice were bled and plasma
prepared. The cytokines/chemokines (pg/ml) was measured using
Bioplex-mouse 23 Plex Cytokines Kit as per manufacturer’s
instruction (Bio-Rad Laboratories, Hercules, CA). These cyto-
kines/chemokines are IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6,
IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-17, Eotaxin, G-
CSF, GM-CSF, IFN-l, keratinocyte chemoattractant (KC),
monocyte chemoattractant protein-1 (MCP-1), MIP-1a, MIP-1b,
TNF-a, and RANTES.
Measurement of colony forming unit of spleen at day +9
Lethally irradiated CD45.2 mice (10.5 Gy) were injected with
whole marrow cells from CD45.1 mice (1610
5 marrow cells per
mouse). The recipient mice were injected subcutaneously with
PBS buffer or AMD3100 at 5 mg/kg every other day beginning at
day +2. At day +9, the mice were sacrificed and the spleen was
harvested and fixed in Bouin’s solution. The colony forming units
of spleen (CFUs-spleen) were counted.
In vivo stem cell mobilization and homing studies shortly
after transplantation
Lethally irradiated C57BL/6 CD45.2 Thy1.2 mice (10.5 Gy)
were injected via tail vein with sorted KTLS hematopoietic stem
cells (2500 cells/mouse) obtained from C57BL/Ka Thy1.1 donor
mice. At 48 hours after transplantation, recipient mice were
injected subq with a single dose of AMD3100 at 5 mg/kg or PBS
control. Twenty-four hours after this injection, the mice were
sacrificed, and the 2 femurs and the spleen were harvested. The
total nucleated cells in the 2 femurs and in the spleen were
measured using the HemavetH counter. The absolute cell numbers
of recipient-origin stem cells (CD45.2
+ KLS cells) and donor
derived stem cells (CD45.1
+ KLS cells) in the spleen and in the
marrow were determined, as described above. Marrow CFUs-GM
and Bursting forming units of erythrocytes (BFUs-E) were
measured using MethocultH GF 3434 (1610
5 cells/dish, triplicate
dishes per individual mouse) as per manufacturer’s instruction
(StemCell Technology, Vancouver, Canada). Percent donor stem
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absolute number of CD45.1
+ KTLS stem cells in the recipient’s
spleen by the number of injected KTLS stem cells. To determine
the mobilization of recipient’s residual marrow stem cells from
marrow, we measured the recipient-origin stem cells (CD45.2
+
KLS cells) in the marrow by flow cytometry as described above.
Measurement of hematopoietic stem/progenitor cell
mobilization after prolonged administration of AMD3100
Transplanted mice that were given AMD3100 at 5 mg/kg body
weight or PBS subcutaneously every other day beginning at day +2
for 60 days were used in this study. Additionally, naı ¨ve mice that
were not transplanted and had not received AMD3100 prior to
the study were used as positive control. The mice were given
AMD3100 at 5 mg/kg body weight or PBS. Blood samples were
collected immediately prior to the injection and 4 hours after
injection, and colony-forming units and white blood cell counts
determined. Colony-forming units were represented as colony
numbers/30 ml blood.
In vivo cell division analysis
KTLS cells obtained from donor CD45.1 mice were labeled
with CFSE [5-(and -6)-carboxyfluorescein diacetate succinimidyl
ester, Molecular Probes, Eugene, OR] at a final concentration of
5 mM and incubated at 37uC for 10 min[53]. After the incubation
period, the cells were immediately washed three times in cold
RPMI/10% FCS. The CFSE-labeled KTLS cells were re-sorted
by flow cytometry to obtain a pure population of cells that were
CFSE
+ c-Kit
+ Thy1
low Lin
2 Sca-1
+. The CFSE-labeled KTLS
cells were then injected into 10.5 Gy irradiated CD45.2 recipient
mice (7,000 KTLS cells/mouse). Beginning at day +2, the
recipient mice were injected subcutaneously with AMD3100 at
5 mg/kg or PBS control every other day. The mice were sacrificed
at day +7, and CFSE positive cells were measured by flow
cytometry. CD45.1
+ cells were analyzed for CSFE content.
In vitro proliferation assay
Marrow cells from normal mice (5610
5/well) were cultured
with various concentrations of AMD3100 or recombinant G-CSF
(NeupogenH, Amgen Inc, Thousand Oaks, CA) at a volume of
200 ml in 96 well plates. Forty-eight hours later, 0.5 mCi of [
3H]
thymidine was added, cells harvested at 18 hrs and the
incorporated [
3H] thymidine detected by using Liquid Scintilla-
tion & Luminescence Counter (PerkinElmer LAS, Shelton, CT).
Secondary transplantation experiment
Bone marrow cells from transplanted C57BL/6 CD45.2
Thy1.2 recipient mice (i.e., primary transplant recipients) were
harvested at day +65, and injected intravenously into lethally
irradiated C57BL/6 CD45.2 Thy1.2 mice (i.e., secondary
transplant recipients) (one to one matched transplant). The
primary transplanted mice received HSCs from donor
C57BL/6 CD45.1 mice and were given post transplant
administration of AMD3100 at 5 mg/kg or PBS subcutaneously
every other day from day +2t o+60. At ,7 weeks after transplant,
the secondary C57BL/6 CD45.2 Thy1.2 transplanted recipient
mice were bled and the CD45.1
+ donor cell contribution in
peripheral granulocytes determined.
Statistical analysis
All values were reported as mean 6 SEM of multiple
measurements. Statistical comparisons between AMD3100-treated
mice and PBS-injected mock mice were done using the Student
t test. Statistical significance was defined as p,0.05.
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